Skip to main content
K

FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)

Event Group
EventKALSHI
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
FDA decision: Saroglitazar by Zydus Therapeutics (in 2026)
|
Vol

1.8K contracts

|
Markets

1

Market snapshot: Nov 22, 2026, 3:00 PM UTC. Prices may have changed.

Market Price Graph

1 market tracked

What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?

kalshi

No data available

All Markets(1)
MarketOutcome price
What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?
Yes 75.5%

Event Overview

FDA decision on Saroglitazar in 2026 If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications. This market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027

Market Resolution Rules

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications. Early close condition: This market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027

Important Notes

  • Markets resolve based on official data sources specified in the rules
  • Resolution may be delayed if official data is not immediately available
  • Kalshi markets are regulated by the CFTC and follow strict resolution procedures
  • Always verify the exact resolution criteria before trading

Markets (1)

Sort
KALSHIHealth
What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?

What will the FDA's decision be on Saroglitazar by Zydus Therapeutics in 2026?

If the FDA's decision on Saroglitazar by Zydus Therapeutics in 2026 is a full approval or an accelerated approval, the market resolves to Yes. Secondary rules: This market will resolve to No if the FDA's decision is a denial (CRL issued), a withdrawal by the sponsor, or a conditional approval — or if no decision is issued. Saroglitazar (sold under the brand name Lipaglyn in India) is an oral small-molecule drug developed by Zydus Therapeutics that is designed to simultaneously activate two molecular switches in the body — called PPAR-alpha and PPAR-gamma — which together regulate how the body handles fats and sugars. Think of it like a dual-dial thermostat for metabolism: turning up both dials at once aims to reduce harmful lipid buildup and improve insulin sensitivity more effectively than nudging just one dial. In the EPICS-III trial, it is being evaluated as a treatment for primary biliary cholangitis, a liver disease distinct from its original metabolic indications. Early close condition: This market will close early if the FDA issues a decision on Saroglitazar before Jan 1, 2027

Yes outcome75.5%
Yes
Volume1.8K contracts
LiquidityN/A
End DateJan 01, 2027
View Details

Share This Event

Share on social media or embed on your website